Loading
thymia
Thymia is a London-based health technology startup founded in 2020, recognized as the world’s first foundational voice biomarker platform. The company utilizes AI-powered gamified tools to objectively measure and monitor mental health symptoms such as depression, anxiety, and ADHD. By replacing traditional self-reported questionnaires with multi-modal digital biomarkers derived from speech patterns, facial expressions, and behavior during specially designed video games, Thymia enables clinicians to assess and track mental health more accurately and efficiently. Thymia offers two main product suites: Apollo, an investigational device set for full launch in 2025, provides clinical insights into major mental health conditions, while Helios, launched in 2024, focuses on measuring mental wellness indicators from just 15 seconds of speech. The platform integrates with various systems, including healthcare, automotive, and telecommunications, to read over 30 clinical-grade biomarkers in real-time. Thymia serves a B2B SaaS model, targeting healthcare providers, insurance companies, employers, and other sectors, and has assessed over 41,000 individuals globally.
Funding
Every round, secondary, debt facility or acquisition involving thymia that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$1M